Rezolute, Inc. (RZLT)
NasdaqCM
Price as at 1 Oct 2026, 00:52 UTC. Quotes are delayed.
Fundamentals
Valuation and ratings
Rezolute, Inc. trades at $4.14. We do not hold enough of the inputs to value this company with the confidence the estimate implies, so we publish no fair value for it rather than a number we would not defend.
About Rezolute, Inc.
Rezolute, Inc., a late-stage rare disease company, focuses developing therapies that treat refractory and debilitating hypoglycemia associated with various forms of hyperinsulinism (HI) in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody which is in Phase 3 clinical trial to treat tumor HI indication, as well as congenital HI. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.
Company profile, industry and headcount are as reported by our data provider and can lag a company's own filings by a reporting period. The annual report is the authority.
Super investor ownership
6 of the funds we track reported a position in their latest SEC 13F filing. Largest first:
- D. E. Shaw, D. E. Shaw & Co., Inc.$9.56M · 0.0% of book
- Cliff Asness, AQR CAPITAL MANAGEMENT LLC$5.24M · 0.0% of book
- Israel Englander, MILLENNIUM MANAGEMENT LLC$2.69M · 0.0% of book
- Two Sigma, TWO SIGMA INVESTMENTS, LP$2.24M · 0.0% of book
- Ken Griffin, CITADEL ADVISORS LLC$512.1K · 0.0% of book
A word of warning on reading these figures: a 13F reports the market value of a holding, so a fund that traded nothing at all still appears to have sold when the price fell. We found 102 companies where the standard reading gives the opposite answer. Only the share count is honest.
Common questions
Which funds own RZLT?
6 of the institutions we track reported a position in RZLT in their most recent SEC 13F filing. A 13F is filed up to 45 days after quarter end, so it tells you what a fund held then, not what it holds now.
Where does SteadyShares get its RZLT data?
Fundamentals for RZLT come from company filings and exchange data, as listed on NasdaqCM; institutional ownership comes from SEC 13F filings. The share price shown was last refreshed on 1 Oct 2026, 00:52 UTC and is delayed. Metrics we do not hold are left out of the page rather than estimated.
The full research page for RZLT, with financial statements, ownership detail, peer comparison and alerts, is free inside the app.
Data from company filings, exchange quotes and SEC EDGAR 13F disclosures. Quotes are delayed. Metrics we do not have are left out rather than estimated. Educational information, not financial advice.